Log in
Log in
E-mail
Password

Show password
Remember
Forgot password ?
Become a member for free
Sign up
Become a member for free
Sign up
New member
Sign up for FREE
New customer
Discover our services
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Cerevel Therapeutics Holdings, Inc.
  6. Financials
    CERE   US15678U1280

CEREVEL THERAPEUTICS HOLDINGS, INC.

(CERE)
  Report
Real-time Estimate Cboe BZX  -  05/16 03:22:00 pm EDT
25.24 USD   +5.61%
05/11Berenberg Bank Adjusts Cerevel Therapeutics Holdings Price Target to $44 From $46, Maintains Buy Rating
MT
05/10Cerevel Therapeutics Q1 Loss Widens
MT
05/10CEREVEL THERAPEUTICS HOLDINGS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Valuation
Fiscal Period: December 2020 2021 2022 2023 2024
Capitalization1 2 1084 7733 544--
Enterprise Value (EV)1 1 7244 2083 2973 3573 520
P/E ratio -8,25x-19,6x-12,7x-10,9x-9,48x
Yield -----
Capitalization / Revenue -----
EV / Revenue -----
EV / EBITDA -11,6x-19,4x-12,6x-11,2x-10,2x
Price to Book -8,28x199x-24,6x398x
Nbr of stocks (in thousands) 127 124147 236148 289--
Reference price (USD) 16,632,423,923,923,9
Announcement Date 03/24/202103/01/2022---
1 USD in Million
Estimates
Income Statement Evolution (Annual data)
Fiscal Period: December 2020 2021 2022 2023 2024
Net sales1 -----
EBITDA1 -149-217-261-299-346
Operating profit (EBIT)1 -149-220-281-329-383
Operating Margin -----
Pre-Tax Profit (EBT)1 -152-225-275-328-383
Net income1 -152-225-275-328-383
Net margin -----
EPS2 -2,01-1,65-1,89-2,20-2,52
Dividend per Share -----
Announcement Date 03/24/202103/01/2022---
1 USD in Million
2 USD
Estimates
Income Statement Evolution (Quarterly data)
Fiscal Period: December 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4
Net sales1 ------
EBITDA ------
Operating profit (EBIT)1 -54,5-64,5-72,5-68,6-69,8-72,9
Operating Margin ------
Pre-Tax Profit (EBT)1 -62,1-59,1-68,3-73,6-76,2-81,2
Net income1 -62,1-59,1-68,3-71,1-70,5-73,9
Net margin ------
EPS2 -0,43-0,40-0,46-0,47-0,48-0,51
Dividend per Share ------
Announcement Date 11/10/202103/01/202205/10/2022---
1 USD in Million
2 USD
Previous periodNext period
Estimates
Balance Sheet Analysis
Fiscal Period: December 2020 2021 2022 2023 2024
Net Debt1 -----
Net Cash position1 38456624718724,0
Leverage (Debt / EBITDA) 2,58x2,60x0,95x0,63x0,07x
Free Cash Flow1 -137-189-264-334-397
ROE (Net Profit / Equities) --46,8%-57,2%-69,3%-75,2%
Shareholders' equity1 -482482473509
ROA (Net Profit / Asset) --39,7%-48,7%-60,4%-66,0%
Assets1 -567566542580
Book Value Per Share2 -3,920,12-0,970,06
Cash Flow per Share -----
Capex1 18,910,511,79,939,98
Capex / Sales -----
Announcement Date 03/24/202103/01/2022---
1 USD in Million
2 USD
Estimates
Key data
Capitalization (USD) 3 544 117 042
Number of employees 228
Free-Float 81,4%
Free-Float capitalization (USD) 2 885 979 994
Avg. Exchange 20 sessions (USD) 11 917 222
Average Daily Capital Traded 0,34%
EPS & Dividend